 Ajay Major
Concepts (194)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lymphoma, Large B-Cell, Diffuse | 5 | 2023 | 94 | 3.280 |
Why?
| | Multiple Myeloma | 6 | 2023 | 100 | 1.800 |
Why?
| | Lymphoma, Non-Hodgkin | 2 | 2023 | 72 | 1.710 |
Why?
| | Hematopoietic Stem Cell Transplantation | 3 | 2022 | 539 | 1.600 |
Why?
| | Hodgkin Disease | 3 | 2022 | 119 | 1.530 |
Why?
| | Medical Oncology | 4 | 2022 | 229 | 1.440 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 10 | 2023 | 1385 | 1.300 |
Why?
| | Neoplasms | 4 | 2022 | 2160 | 1.160 |
Why?
| | Immunotherapy, Adoptive | 3 | 2023 | 191 | 1.080 |
Why?
| | Antibodies, Bispecific | 1 | 2023 | 33 | 0.920 |
Why?
| | Neoplasm Recurrence, Local | 4 | 2023 | 895 | 0.920 |
Why?
| | Lymphoproliferative Disorders | 2 | 2023 | 46 | 0.850 |
Why?
| | Purpura, Thrombocytopenic, Idiopathic | 1 | 2021 | 15 | 0.820 |
Why?
| | Plasma Exchange | 1 | 2021 | 21 | 0.820 |
Why?
| | Vaccination | 2 | 2021 | 1218 | 0.810 |
Why?
| | Lymphoma, B-Cell | 2 | 2022 | 85 | 0.790 |
Why?
| | Peripheral Nervous System Diseases | 1 | 2022 | 122 | 0.790 |
Why?
| | Psychosocial Support Systems | 1 | 2021 | 12 | 0.790 |
Why?
| | Lymphohistiocytosis, Hemophagocytic | 1 | 2021 | 28 | 0.770 |
Why?
| | Internship and Residency | 2 | 2021 | 1005 | 0.770 |
Why?
| | Drug Costs | 1 | 2020 | 93 | 0.700 |
Why?
| | Lymphoma, Follicular | 1 | 2019 | 29 | 0.700 |
Why?
| | Positron Emission Tomography Computed Tomography | 1 | 2019 | 71 | 0.680 |
Why?
| | Internal Medicine | 1 | 2021 | 215 | 0.670 |
Why?
| | Brain Neoplasms | 2 | 2017 | 1019 | 0.670 |
Why?
| | Neoplasms, Second Primary | 1 | 2019 | 93 | 0.650 |
Why?
| | Adrenal Insufficiency | 1 | 2018 | 30 | 0.620 |
Why?
| | Lymphoma, Large-Cell, Anaplastic | 1 | 2017 | 14 | 0.600 |
Why?
| | Oncologists | 1 | 2017 | 31 | 0.600 |
Why?
| | Humans | 43 | 2024 | 118257 | 0.590 |
Why?
| | Mental Health Services | 1 | 2021 | 331 | 0.590 |
Why?
| | Medicare | 2 | 2023 | 664 | 0.560 |
Why?
| | Immunocompromised Host | 1 | 2018 | 198 | 0.560 |
Why?
| | Lymphoma | 3 | 2023 | 179 | 0.550 |
Why?
| | Cyclophosphamide | 3 | 2022 | 222 | 0.550 |
Why?
| | Empathy | 1 | 2017 | 142 | 0.540 |
Why?
| | Cancer Survivors | 1 | 2019 | 201 | 0.530 |
Why?
| | Mental Health | 1 | 2021 | 567 | 0.530 |
Why?
| | Health Personnel | 1 | 2021 | 578 | 0.530 |
Why?
| | Health Services Accessibility | 1 | 2021 | 776 | 0.510 |
Why?
| | Quality of Life | 2 | 2022 | 2355 | 0.510 |
Why?
| | Students, Medical | 2 | 2021 | 311 | 0.490 |
Why?
| | Bullying | 1 | 2014 | 23 | 0.470 |
Why?
| | Curriculum | 1 | 2020 | 908 | 0.470 |
Why?
| | Transplantation, Autologous | 3 | 2023 | 191 | 0.460 |
Why?
| | Healthcare Disparities | 1 | 2018 | 494 | 0.450 |
Why?
| | Mental Disorders | 1 | 2021 | 935 | 0.440 |
Why?
| | Physicians | 1 | 2021 | 792 | 0.430 |
Why?
| | Hematology | 2 | 2022 | 12 | 0.420 |
Why?
| | Pediatrics | 1 | 2020 | 980 | 0.420 |
Why?
| | Delivery of Health Care | 1 | 2018 | 862 | 0.400 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2017 | 610 | 0.400 |
Why?
| | Faculty, Medical | 1 | 2014 | 252 | 0.390 |
Why?
| | Central Nervous System Neoplasms | 2 | 2023 | 128 | 0.380 |
Why?
| | Education, Medical | 1 | 2014 | 239 | 0.380 |
Why?
| | Dexamethasone | 5 | 2023 | 319 | 0.380 |
Why?
| | Skin Neoplasms | 1 | 2017 | 762 | 0.350 |
Why?
| | Vincristine | 2 | 2021 | 99 | 0.350 |
Why?
| | Etoposide | 2 | 2021 | 149 | 0.350 |
Why?
| | Public Health Surveillance | 2 | 2020 | 57 | 0.340 |
Why?
| | Information Dissemination | 2 | 2022 | 193 | 0.330 |
Why?
| | Doxorubicin | 2 | 2021 | 301 | 0.320 |
Why?
| | Fatal Outcome | 2 | 2017 | 286 | 0.290 |
Why?
| | Databases, Factual | 2 | 2022 | 1196 | 0.270 |
Why?
| | Neoplasm Staging | 2 | 2019 | 1221 | 0.260 |
Why?
| | Platelet Factor 4 | 2 | 2022 | 22 | 0.260 |
Why?
| | Treatment Outcome | 5 | 2023 | 9319 | 0.260 |
Why?
| | Aged | 9 | 2023 | 19594 | 0.260 |
Why?
| | Rituximab | 2 | 2023 | 153 | 0.240 |
Why?
| | Disease Management | 2 | 2018 | 566 | 0.240 |
Why?
| | Methotrexate | 2 | 2023 | 227 | 0.240 |
Why?
| | Lung Neoplasms | 1 | 2017 | 2216 | 0.240 |
Why?
| | Lymphoma, T-Cell, Peripheral | 1 | 2024 | 15 | 0.240 |
Why?
| | Male | 12 | 2023 | 57476 | 0.230 |
Why?
| | Cell- and Tissue-Based Therapy | 1 | 2023 | 54 | 0.230 |
Why?
| | Middle Aged | 8 | 2023 | 27511 | 0.230 |
Why?
| | Education, Medical, Graduate | 3 | 2022 | 399 | 0.220 |
Why?
| | Melphalan | 1 | 2022 | 30 | 0.220 |
Why?
| | Bortezomib | 1 | 2022 | 42 | 0.220 |
Why?
| | Watchful Waiting | 1 | 2022 | 55 | 0.210 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2023 | 73 | 0.210 |
Why?
| | Disseminated Intravascular Coagulation | 1 | 2022 | 29 | 0.210 |
Why?
| | Amyloidosis | 1 | 2022 | 40 | 0.210 |
Why?
| | Africa | 1 | 2022 | 99 | 0.210 |
Why?
| | Platelet Count | 1 | 2021 | 81 | 0.200 |
Why?
| | Antimetabolites, Antineoplastic | 1 | 2022 | 83 | 0.200 |
Why?
| | Young Adult | 4 | 2022 | 10731 | 0.200 |
Why?
| | Infectious Disease Transmission, Patient-to-Professional | 1 | 2021 | 20 | 0.200 |
Why?
| | Sirolimus | 1 | 2022 | 195 | 0.200 |
Why?
| | Fellowships and Scholarships | 2 | 2022 | 250 | 0.190 |
Why?
| | Prednisone | 1 | 2021 | 235 | 0.190 |
Why?
| | Health Occupations | 1 | 2020 | 30 | 0.190 |
Why?
| | Frailty | 1 | 2023 | 116 | 0.190 |
Why?
| | Artificial Intelligence | 1 | 2021 | 137 | 0.190 |
Why?
| | Prognosis | 2 | 2018 | 3424 | 0.190 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2022 | 341 | 0.190 |
Why?
| | Patient Reported Outcome Measures | 1 | 2022 | 251 | 0.180 |
Why?
| | Thrombocytopenia | 1 | 2022 | 184 | 0.180 |
Why?
| | Blood Coagulation Disorders | 1 | 2022 | 166 | 0.180 |
Why?
| | Survivorship | 1 | 2020 | 38 | 0.180 |
Why?
| | Surveys and Questionnaires | 2 | 2022 | 4684 | 0.180 |
Why?
| | Retrospective Studies | 5 | 2023 | 12929 | 0.180 |
Why?
| | Personal Satisfaction | 1 | 2021 | 183 | 0.170 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2022 | 369 | 0.170 |
Why?
| | Botulism | 1 | 2019 | 3 | 0.170 |
Why?
| | Heroin Dependence | 1 | 2019 | 19 | 0.170 |
Why?
| | Medical Informatics | 1 | 2020 | 97 | 0.170 |
Why?
| | Female | 9 | 2023 | 61262 | 0.170 |
Why?
| | Program Development | 1 | 2021 | 355 | 0.170 |
Why?
| | Pandemics | 3 | 2022 | 1338 | 0.170 |
Why?
| | Neoplasm Grading | 1 | 2019 | 257 | 0.170 |
Why?
| | Adult | 6 | 2022 | 31325 | 0.170 |
Why?
| | SEER Program | 1 | 2019 | 205 | 0.170 |
Why?
| | Needs Assessment | 1 | 2020 | 325 | 0.160 |
Why?
| | Immunosuppressive Agents | 2 | 2023 | 682 | 0.160 |
Why?
| | Machine Learning | 1 | 2021 | 321 | 0.160 |
Why?
| | Education, Medical, Undergraduate | 1 | 2021 | 199 | 0.160 |
Why?
| | Social Media | 1 | 2020 | 133 | 0.160 |
Why?
| | Substance Abuse, Intravenous | 1 | 2019 | 80 | 0.160 |
Why?
| | Antibodies, Monoclonal, Humanized | 2 | 2022 | 665 | 0.150 |
Why?
| | Mediastinal Neoplasms | 1 | 2017 | 35 | 0.150 |
Why?
| | Prednisolone | 1 | 2017 | 76 | 0.150 |
Why?
| | Narration | 1 | 2017 | 47 | 0.150 |
Why?
| | Symptom Assessment | 1 | 2018 | 123 | 0.150 |
Why?
| | Immunotherapy | 1 | 2021 | 493 | 0.140 |
Why?
| | Program Evaluation | 1 | 2021 | 838 | 0.140 |
Why?
| | Vaccines | 1 | 2022 | 380 | 0.140 |
Why?
| | Adaptation, Psychological | 1 | 2021 | 545 | 0.140 |
Why?
| | Risk Factors | 3 | 2021 | 8958 | 0.140 |
Why?
| | Research | 1 | 2020 | 406 | 0.140 |
Why?
| | Aged, 80 and over | 4 | 2023 | 6541 | 0.140 |
Why?
| | Pilot Projects | 1 | 2021 | 1405 | 0.140 |
Why?
| | Burnout, Professional | 1 | 2022 | 322 | 0.140 |
Why?
| | Survivors | 1 | 2019 | 411 | 0.140 |
Why?
| | Kaplan-Meier Estimate | 1 | 2018 | 840 | 0.140 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2017 | 197 | 0.130 |
Why?
| | Proportional Hazards Models | 1 | 2018 | 1124 | 0.130 |
Why?
| | Receptor Protein-Tyrosine Kinases | 1 | 2017 | 229 | 0.130 |
Why?
| | Combined Modality Therapy | 1 | 2018 | 1163 | 0.130 |
Why?
| | Anxiety | 1 | 2021 | 845 | 0.120 |
Why?
| | Attitude of Health Personnel | 1 | 2021 | 990 | 0.120 |
Why?
| | Clinical Competence | 1 | 2020 | 950 | 0.110 |
Why?
| | Child | 3 | 2022 | 19033 | 0.110 |
Why?
| | Stress, Psychological | 1 | 2021 | 967 | 0.110 |
Why?
| | T-Lymphocytes | 1 | 2021 | 1770 | 0.110 |
Why?
| | Cytokines | 1 | 2021 | 1880 | 0.110 |
Why?
| | Depression | 1 | 2021 | 1133 | 0.110 |
Why?
| | Age Factors | 1 | 2020 | 2990 | 0.110 |
Why?
| | Adolescent | 3 | 2019 | 18364 | 0.110 |
Why?
| | Cell Differentiation | 1 | 2019 | 1746 | 0.100 |
Why?
| | Registries | 1 | 2020 | 1806 | 0.100 |
Why?
| | Prevalence | 1 | 2018 | 2321 | 0.100 |
Why?
| | Colorado | 1 | 2021 | 4178 | 0.100 |
Why?
| | Antibodies, Monoclonal | 1 | 2017 | 1279 | 0.100 |
Why?
| | Electronic Health Records | 1 | 2017 | 809 | 0.090 |
Why?
| | United States | 2 | 2023 | 12491 | 0.080 |
Why?
| | Antineoplastic Agents | 1 | 2017 | 1967 | 0.070 |
Why?
| | Cytarabine | 1 | 2023 | 53 | 0.060 |
Why?
| | Cell Transplantation | 1 | 2023 | 38 | 0.060 |
Why?
| | Imides | 1 | 2022 | 10 | 0.050 |
Why?
| | Proteasome Inhibitors | 1 | 2022 | 43 | 0.050 |
Why?
| | Herpesvirus 4, Human | 1 | 2023 | 126 | 0.050 |
Why?
| | Frail Elderly | 1 | 2023 | 105 | 0.050 |
Why?
| | Biotin | 1 | 2022 | 24 | 0.050 |
Why?
| | Neoplasm, Residual | 1 | 2022 | 103 | 0.050 |
Why?
| | Injections, Spinal | 1 | 2022 | 105 | 0.050 |
Why?
| | Geriatric Assessment | 1 | 2023 | 182 | 0.050 |
Why?
| | Education, Premedical | 1 | 2021 | 4 | 0.050 |
Why?
| | Blogging | 1 | 2021 | 8 | 0.050 |
Why?
| | Blood Component Transfusion | 1 | 2022 | 69 | 0.050 |
Why?
| | Professionalism | 1 | 2021 | 13 | 0.050 |
Why?
| | Central Nervous System | 1 | 2023 | 243 | 0.050 |
Why?
| | Heparin | 1 | 2022 | 230 | 0.050 |
Why?
| | Plasma | 1 | 2022 | 194 | 0.050 |
Why?
| | Activities of Daily Living | 1 | 2023 | 353 | 0.050 |
Why?
| | Lymphocytes | 1 | 2022 | 346 | 0.050 |
Why?
| | Bayes Theorem | 1 | 2021 | 341 | 0.050 |
Why?
| | Writing | 1 | 2021 | 88 | 0.040 |
Why?
| | Dysphonia | 1 | 2019 | 14 | 0.040 |
Why?
| | Lymph Nodes | 1 | 2022 | 443 | 0.040 |
Why?
| | Blood Transfusion | 1 | 2022 | 278 | 0.040 |
Why?
| | Drug Contamination | 1 | 2019 | 54 | 0.040 |
Why?
| | Paraplegia | 1 | 2019 | 60 | 0.040 |
Why?
| | Muscle Weakness | 1 | 2019 | 82 | 0.040 |
Why?
| | Diagnostic Errors | 1 | 2019 | 162 | 0.040 |
Why?
| | Dyspnea | 1 | 2019 | 201 | 0.040 |
Why?
| | Deglutition Disorders | 1 | 2019 | 128 | 0.040 |
Why?
| | Hepatitis C, Chronic | 1 | 2019 | 151 | 0.040 |
Why?
| | Incidence | 1 | 2023 | 2413 | 0.040 |
Why?
| | Positron-Emission Tomography | 1 | 2017 | 298 | 0.030 |
Why?
| | Recurrence | 1 | 2017 | 971 | 0.030 |
Why?
| | Risk Assessment | 1 | 2023 | 3043 | 0.030 |
Why?
| | Cohort Studies | 1 | 2023 | 5078 | 0.030 |
Why?
| | Cross-Sectional Studies | 1 | 2022 | 4522 | 0.020 |
Why?
|
|
Major's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|